Segmented Information and Economic Dependence

9 Months Ended

Jan. 31, 2024

Disclosure of operating segments [abstract]

SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE

13.

SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE

At January 31, 2024 and April 30, 2023, the Company has one reportable segment, being antibody production and related services.

The Company’s revenues are allocated to geographic regions for the three and nine months ended January 31, 2024 and 2023 as follows:


	Three months ended January 31,				Nine months ended January 31,
(in thousands)	2024 $		2023 $		2024 $		2023 $
United States of America		3,369		3,006		9,009		6,942
Europe		2,594		1,889		7,960		6,816
Canada		112		121		356		518
Australia		31		90		179		326
Other		115		65		555		442
		6,221		5,171		18,059		15,044

The Company’s revenues are allocated according to revenue types for the three and nine months ended January 31, 2024 and 2023 as follows:


	Three months ended January 31,				Nine months ended January 31,
(in thousands)	2024 $		2023 $		2024 $		2023 $
Project revenue		5,774		4,754		16,508		13,817
Product sales revenue		395		363		1,372		1,054
Cryostorage revenue		52		54		179		173
		6,221		5,171		18,059		15,044

The Company’s non-current assets are allocated to geographic regions as of January 31, 2024 and April 30, 2023 as follows:


	January 31, 2024 $		April 30, 2023 $
North America - Corporate		81		89
North America		4,650		1,025
Belgium		37,515		40,406
Netherlands		21,386		19,501
		63,632		61,021

Geographic segmentation of the Company’s net income (loss) for the three and nine months ended January 31, 2024 and 2023 is as follows:


	Three months ended January 31,						Nine months ended January 31,
(in thousands)	2024 $			2023 $			2024 $			2023 $
North America - Corporate		(3,335	)		(620	)		(6,022	)		(4,500	)
North America		765			(3,146	)		51			(14,327	)
Belgium		(1,488	)		(1,267	)		(3,829	)		(3,276	)
Netherlands		1,118			334			668			672
		(2,940	)		(4,699	)		(9,132	)		(21,431	)

Geographic segmentation of the interest and accretion, and amortization and depreciation for the three and nine months ended January 31, 2024 and 2023 is as follows:


	Three months ended January 31,					Nine months ended January 31,
Interest and accretion (in thousands)	2024 $			2023 $		2024 $		2023 $
North America - Corporate		14			2		4		17
North America		95			3		175		14
Belgium		(37	)		3		—		12
Netherlands		114			111		352		169
		186			119		531		212


	Three months ended January 31,				Nine months ended January 31,
Amortization and depreciation (in thousands)	2024 $		2023 $		2024 $		2023 $
North America - Corporate		3		4		9		11
North America		137		195		439		563
Belgium		608		554		1,817		1,717
Netherlands		561		935		1,891		2,411
		1,309		1,688		4,156		4,702